Last reviewed · How we verify
SARS-CoV-2 mRNA vaccine — Competitive Intelligence Brief
phase 3
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
SARS-CoV-2 mRNA vaccine (SARS-CoV-2 mRNA vaccine) — TruDiagnostic. The SARS-CoV-2 mRNA vaccine works by instructing cells to produce a piece of the SARS-CoV-2 virus, triggering an immune response to fight the virus.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SARS-CoV-2 mRNA vaccine TARGET | SARS-CoV-2 mRNA vaccine | TruDiagnostic | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SARS-CoV-2 mRNA vaccine CI watch — RSS
- SARS-CoV-2 mRNA vaccine CI watch — Atom
- SARS-CoV-2 mRNA vaccine CI watch — JSON
- SARS-CoV-2 mRNA vaccine alone — RSS
Cite this brief
Drug Landscape (2026). SARS-CoV-2 mRNA vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/sars-cov-2-mrna-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab